IN2014MN01495A - - Google Patents
Info
- Publication number
- IN2014MN01495A IN2014MN01495A IN1495MUN2014A IN2014MN01495A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A IN 1495MUN2014 A IN1495MUN2014 A IN 1495MUN2014A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A
- Authority
- IN
- India
- Prior art keywords
- metal
- formula
- group
- mixed
- patient
- Prior art date
Links
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004696 coordination complex Chemical class 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 229910052723 transition metal Inorganic materials 0.000 abstract 2
- 150000003624 transition metals Chemical class 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
- C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261583377P | 2012-01-05 | 2012-01-05 | |
| US201261656178P | 2012-06-06 | 2012-06-06 | |
| US201261668679P | 2012-07-06 | 2012-07-06 | |
| US201261721575P | 2012-11-02 | 2012-11-02 | |
| PCT/IB2012/056959 WO2013102806A1 (en) | 2012-01-05 | 2012-12-04 | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01495A true IN2014MN01495A (ko) | 2015-04-17 |
Family
ID=47559596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1495MUN2014 IN2014MN01495A (ko) | 2012-01-05 | 2012-12-04 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9187509B2 (ko) |
| EP (1) | EP2800755B1 (ko) |
| JP (2) | JP6131271B2 (ko) |
| KR (1) | KR102086022B1 (ko) |
| CN (2) | CN107353313B (ko) |
| AU (1) | AU2012364227B2 (ko) |
| BR (1) | BR112014016497B1 (ko) |
| CA (1) | CA2862736C (ko) |
| ES (1) | ES2683038T3 (ko) |
| HK (1) | HK1245276B (ko) |
| IN (1) | IN2014MN01495A (ko) |
| MX (1) | MX2014008247A (ko) |
| RU (2) | RU2765805C2 (ko) |
| WO (1) | WO2013102806A1 (ko) |
| ZA (1) | ZA201404904B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107353313B (zh) | 2012-01-05 | 2019-04-09 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
| MX376321B (es) * | 2012-11-02 | 2025-03-07 | Egetis Therapeutics Ab | Usos para el tratamiento de cancer. |
| US10233205B2 (en) | 2015-08-07 | 2019-03-19 | Auburn University | Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species |
| EP3842040B1 (en) | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| KR20190085967A (ko) | 2016-11-14 | 2019-07-19 | 칼슨-튜너 인베스트 에이에스 | 화학요법으로-유도된 psn을 예방 및 치료하기 위한 비-전이 금속 배위된 디피리독실 화합물의 용도 |
| WO2022244757A1 (ja) | 2021-05-18 | 2022-11-24 | 株式会社Ｌｔｔバイオファーマ | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091169A (en) | 1987-05-08 | 1992-02-25 | Salutar, Inc. | Dipyridoxyl phosphate NMRI contrast agent compositions |
| AR246956A1 (es) * | 1987-05-08 | 1994-10-31 | Salutar Inc | Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste. |
| US5223243A (en) | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| GB9727224D0 (en) | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| AU1770299A (en) * | 1997-12-23 | 1999-07-19 | Nycomed Imaging As | Nitric oxide releasing chelating agents and their therapeutic use |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| DE10359628A1 (de) | 2003-12-18 | 2005-07-21 | Oxeno Olefinchemie Gmbh | Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| KR101678865B1 (ko) * | 2007-12-14 | 2016-11-23 | 플레드파르마 에이비 | 암의 치료에 사용하기 위한 화합물들 |
| US8414866B2 (en) * | 2007-12-17 | 2013-04-09 | Ge Healthcare As | Method of magnetic resonance imaging of the heart with paramagnetic MN2+ |
| CN105688215A (zh) | 2009-07-06 | 2016-06-22 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| CN107353313B (zh) * | 2012-01-05 | 2019-04-09 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
-
2012
- 2012-12-04 CN CN201710588057.1A patent/CN107353313B/zh active Active
- 2012-12-04 JP JP2014550770A patent/JP6131271B2/ja active Active
- 2012-12-04 IN IN1495MUN2014 patent/IN2014MN01495A/en unknown
- 2012-12-04 ES ES12815799.7T patent/ES2683038T3/es active Active
- 2012-12-04 KR KR1020147021727A patent/KR102086022B1/ko not_active Expired - Fee Related
- 2012-12-04 CN CN201280070691.1A patent/CN104169291B/zh active Active
- 2012-12-04 WO PCT/IB2012/056959 patent/WO2013102806A1/en not_active Ceased
- 2012-12-04 US US14/369,153 patent/US9187509B2/en active Active
- 2012-12-04 BR BR112014016497-5A patent/BR112014016497B1/pt active IP Right Grant
- 2012-12-04 RU RU2017119660A patent/RU2765805C2/ru active
- 2012-12-04 CA CA2862736A patent/CA2862736C/en active Active
- 2012-12-04 RU RU2014132184A patent/RU2622646C2/ru active
- 2012-12-04 MX MX2014008247A patent/MX2014008247A/es active IP Right Grant
- 2012-12-04 EP EP12815799.7A patent/EP2800755B1/en active Active
- 2012-12-04 AU AU2012364227A patent/AU2012364227B2/en active Active
-
2014
- 2014-07-02 ZA ZA2014/04904A patent/ZA201404904B/en unknown
-
2015
- 2015-10-26 US US14/922,555 patent/US9597334B2/en active Active
-
2017
- 2017-02-28 US US15/445,588 patent/US10111893B2/en active Active
- 2017-04-17 JP JP2017081176A patent/JP6316479B2/ja active Active
-
2018
- 2018-04-04 HK HK18104469.4A patent/HK1245276B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| PH12015502839B1 (en) | Antiviral compounds | |
| EA201301154A1 (ru) | Разветвленные производные 3-фенилпропионовой кислоты и их применение | |
| MX2014013660A (es) | Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b. | |
| IN2014MN01495A (ko) | ||
| PH12015501316A1 (en) | Heterocyclic compound | |
| MX352928B (es) | Compuestos de piridazina-amida. | |
| MY170262A (en) | Dicarboxylic acid compound | |
| MX2014011921A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. | |
| MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| NZ711343A (en) | Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation | |
| MY170637A (en) | Macrocyclic compound and methods for its production | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| GEP20166448B (en) | Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate | |
| IN2012DN05192A (ko) | ||
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| MX2016004967A (es) | Tratamiento para cancer pancreatico. | |
| MX2015002705A (es) | Compuestos de piridinona para usarse en terapia fotodinamica. | |
| MX2012004914A (es) | Compuestos de 2-aminoindol y metodos para el tratamiento de la malaria. | |
| TH149370A (th) | คาลมากาโฟดิเพอ, ตัวยาทางเคมีแบบใหม่, และสารประกอบเชิงซ้อนของโลหะผสมอื่นๆ, วิธีการของการเตรียม, องค์ประกอบ, และวิธีการของการรักษา (Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment) | |
| NZ725365A (en) | Antiviral compounds inhibitors of hcv ns5b | |
| UA92303C2 (ru) | КОМПЛЕКСНАЯ СОЛЬ Са-АЛЬДОНОВОЙ И АМИНОКАРБОНОВОЙ КИСЛОТ, ПРОЯВЛЯЮЩАЯ ПРОТИВООПУХОЛЕВОЕ ДЕЙСТВИЕ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ |